Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

This study is testing a drug called depemokimab — a long-acting biologic injection given only twice a year — for people with moderate-to-severe COPD who have frequent flare-ups and high levels of a type of immune cell called eosinophils. This drug targets a specific immune pathway (called type 2 inflammation) that may contribute to COPD in certain patients. **You may be eligible if...** - You are between 40 and 80 years old - You have a confirmed diagnosis of COPD for at least 1 year - Your breathing tests show moderate-to-severe airflow limitation - You have had at least 2 moderate or 1 severe COPD flare-up in the past year - Your blood eosinophil count is elevated - You are a current or former smoker **You may NOT be eligible if...** - You have asthma as your primary diagnosis - Your COPD flare-ups are very infrequent - Your eosinophil count is normal or low - You have certain other serious lung or immune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.